糖蛋白IIb/IIIa抑制剂在院外心脏骤停并接受经皮冠状动脉介入治疗患者中的安全性与获益
该回顾性队列研究纳入2007年1月至2017年12月间因心源性院外心脏骤停接受PCI的连续患者385例,其中41.3%(159例)使用糖蛋白IIb/IIIa抑制剂(GPi)。GPi组与非GPi组的住院期间明确支架血栓发生率(11.9% vs 7.1%,p=0.10)和住院死亡率(48.6% vs 49.3%,p=0.68)无显著差异。GPi组任何出血(33.3% vs 19.6%,p=0.002)和主要出血(BARC 3-5)(21.9% vs 16.8%,p=0.007)发生率显著更高。多因素分析显示GPi使用是主要出血的预测因素(OR 1.81;95%CI 1.06-3.08;p=0.03)。
要点
- 院外心脏骤停接受PCI患者中,GPi使用与主要出血风险增加独立相关(OR 1.81;95%CI 1.06-3.08;p=0.03)。
- GPi组任何出血发生率33.3% vs 非GPi组19.6%(p=0.002),主要出血(BARC 3-5)21.9% vs 16.8%(p=0.007)。
- 住院期间明确支架血栓发生率GPi组11.9% vs 非GPi组7.1%,差异未达统计学显著(p=0.10)。
- 住院死亡率GPi组48.6% vs 非GPi组49.3%,无显著差异(p=0.68)。
- GPi组患者更年轻、既往PCI史较少、PCI前TIMI血流0或1级更常见、血栓抽吸使用更多。
适用人群与场景
- 2007年1月至2017年12月间因心源性院外心脏骤停接受经皮冠状动脉介入治疗的连续患者。
研究设计与关键结果
- 回顾性纳入385例因心源性院外心脏骤停接受PCI的患者,GPi使用率为41.3%(159例)。
- GPi组与非GPi组住院期间明确支架血栓发生率分别为11.9%和7.1%,p=0.10,无显著差异。
- GPi组与非GPi组住院死亡率分别为48.6%和49.3%,p=0.68,无显著差异。
- GPi组任何出血发生率33.3%,非GPi组19.6%,p=0.002,GPi组更高。
- GPi组主要出血(BARC 3-5)发生率21.9%,非GPi组16.8%,p=0.007,GPi组更高。
- 多因素分析显示GPi使用是主要出血的预测因素(OR 1.81;95%CI 1.06-3.08;p=0.03)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在心源性院外心脏骤停接受PCI的患者中,GPi使用与主要出血事件风险增加相关,而住院期间支架血栓或死亡无差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Out of hospital cardiac arrest (OHCA) patients requiring percutaneous coronary intervention (PCI) are at higher risk of both stent thrombosis and bleeding. The use of aggressive antiplatelet therapy could lead to a higher risk of bleeding in these patients. Indeed, data on glycoprotein IIb/IIIa inhibitor (GPi) use in this specific indication is scarce.
AIM: We sought to evaluate the benefit and safety of GPi use in OHCA patients requiring PCI.
METHODS AND RESULTS: Between January 2007 and December 2017, we retrospectively included all consecutive patients treated with PCI for an OHCA from cardiac cause. Clinical, procedural data and in-hospital outcomes were collected. Three hundred and eighty-five patients were included. GPi were administrated in 41.3% of cases (159 patients). Patients who received GPi were younger, had less prior PCI, more often a TIMI 0 or 1 flow before PCI and thromboaspiration use. There were no differences regarding in-hospital definite stent thrombosis among the two groups (11.9% in the GPi group vs 7.1% in the non-GPi group, p = 0.10) or in-hospital mortality (48.6% vs 49.3%, p = 0.68). The incidence of any bleeding (33.3% vs. 19.6%; p = 0.002), and major bleeding (BARC 3-5) (21.9% vs. 16.8%; p = 0.007) was significantly higher in patients receiving GPi. Indeed, using multivariate analysis, GPi use was predictor of major bleeding (OR: 1.81; 95% CI: 1.06-3.08; p = 0.03).
CONCLUSIONS: In patients treated with PCI for OHCA from cardiac cause, GPi use was associated with an increased risk of major bleeding events, without difference on in-hospital stent thrombosis or death.
参考来源
- Picard F, Sokoloff A, Pham V, et al. Safety and benefit of Glycoprotein IIb/IIIa inhibitors in out of hospital cardiac arrest patients treated with percutaneous coronary intervention. Resuscitation. 2020. PMID: 33129912. doi:10.1016/j.resuscitation.2020.10.030
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。